{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:27:45Z","timestamp":1770895665583,"version":"3.50.1"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:00:00Z","timestamp":1637971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["269864"],"award-info":[{"award-number":["269864"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority","doi-asserted-by":"publisher","award":["2019105"],"award-info":[{"award-number":["2019105"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jsat.2021.108667","type":"journal-article","created":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T11:07:13Z","timestamp":1638011233000},"page":"108667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["\u2018Not at all what I had expected\u2019: Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study"],"prefix":"10.1016","volume":"136","author":[{"given":"Ida Halvorsen","family":"Brenna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Marciuch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bente","family":"Birkeland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marius","family":"Veseth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bente","family":"R\u00f8stad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Else-Marie","family":"L\u00f8berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin Klemmetsby","family":"Solli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Tanum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bente","family":"Weimand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2021.108667_bb0005","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/164_2019_268","article-title":"The rise and fall of kappa-opioid receptors in drug abuse research","volume":"258","author":"Banks","year":"2020","journal-title":"Handbook of experimental pharmacology"},{"key":"10.1016\/j.jsat.2021.108667_bb0010","article-title":"Participants' treatment perspectives on a clinical trial on the use of extended-release naltrexone for substance use disorders: Considerations for future clinical research","author":"Bardwell","year":"2020","journal-title":"Journal of Addiction Medicine"},{"issue":"3","key":"10.1016\/j.jsat.2021.108667_bb0015","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/10550887.2012.694598","article-title":"Maintenance medication for opiate addiction: The foundation of recovery","volume":"31","author":"Bart","year":"2012","journal-title":"Journal of Addictive Diseases"},{"key":"10.1016\/j.jsat.2021.108667_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2016.01.003","article-title":"Peer-delivered recovery support Services for Addictions in the United States: A systematic review","volume":"63","author":"Bassuk","year":"2016","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108667_bb0025","series-title":"Scientific realism and human emancipation","author":"Bhaskar","year":"2009"},{"issue":"1\u20133","key":"10.1016\/j.jsat.2021.108667_bb0030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.drugalcdep.2011.10.018","article-title":"Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: Dose\u2013effects and time-course","volume":"123","author":"Bigelow","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"issue":"3","key":"10.1016\/j.jsat.2021.108667_bb0035","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/13556210220139541","article-title":"Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: A report of two cases","volume":"7","author":"Brewer","year":"2002","journal-title":"Addiction Biology"},{"issue":"8","key":"10.1016\/j.jsat.2021.108667_bb0040","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.cpr.2013.07.007","article-title":"Drop-out from addiction treatment: A systematic review of risk factors","volume":"33","author":"Brorson","year":"2013","journal-title":"Clinical Psychology Review"},{"issue":"1\u20134","key":"10.1016\/j.jsat.2021.108667_bb0045","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1037\/1064-1297.1.1-4.55","article-title":"Drug effect expectancies and addictive behavior change","volume":"1","author":"Brown","year":"1993","journal-title":"Experimental and Clinical Psychopharmacology"},{"issue":"10","key":"10.1016\/j.jsat.2021.108667_bb0050","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.addbeh.2014.05.007","article-title":"Factors associated with dropout among patients in opioid maintenance treatment (OMT) and predictors of re-entry.A national registry-based study","volume":"39","author":"Bukten","year":"2014","journal-title":"Addictive Behaviors"},{"issue":"1","key":"10.1016\/j.jsat.2021.108667_bb0055","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/npp.2015.258","article-title":"Dynorphin, dysphoria, and dependence: The stress of addiction","volume":"41","author":"Chavkin","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20133","key":"10.1016\/j.jsat.2021.108667_bb0060","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.drugalcdep.2007.11.003","article-title":"Mortality prior to, during and after opioid maintenance treatment (OMT): A national prospective cross-registry study","volume":"94","author":"Clausen","year":"2008","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108667_bb0065","author":"<collab>WHO"},{"issue":"4","key":"10.1016\/j.jsat.2021.108667_bb0070","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s002130100909","article-title":"Depot naltrexone: Long-lasting antagonism of the effects of heroin in humans","volume":"159","author":"Comer","year":"2002","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.jsat.2021.108667_bb0075","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jsat.2011.05.001","article-title":"Risk of drug-related mortality during periods of transition in methadone maintenance treatment: A cohort study","volume":"41","author":"Cousins","year":"2011","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108667_bb0080","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pnpbp.2015.01.001","article-title":"Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment","volume":"62","author":"Crowley","year":"2015","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"issue":"1","key":"10.1016\/j.jsat.2021.108667_bb0085","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13063-019-3995-y","article-title":"A call for consensus in defining efficacy in clinical trials for opioid addiction: Combined results from a systematic review and qualitative study in patients receiving pharmacological assisted therapy for opioid use disorder","volume":"21","author":"Dennis","year":"2020","journal-title":"Trials"},{"issue":"6","key":"10.1016\/j.jsat.2021.108667_bb0090","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/npp.2014.330","article-title":"Evaluation of opioid modulation in major depressive disorder","volume":"40","author":"Ehrich","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.jsat.2021.108667_bb0095","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1037\/pst0000175","article-title":"Therapist empathy and client outcome: An updated meta-analysis","volume":"55","author":"Elliott","year":"2018","journal-title":"Psychotherapy"},{"key":"10.1016\/j.jsat.2021.108667_bb0100","author":"EMCDDA"},{"issue":"7","key":"10.1016\/j.jsat.2021.108667_bb0105","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41380-018-0284-1","article-title":"Opioid system modulation with buprenorphine\/samidorphan combination for major depressive disorder: Two randomized controlled studies","volume":"25","author":"Fava","year":"2020","journal-title":"Molecular Psychiatry"},{"issue":"3","key":"10.1016\/j.jsat.2021.108667_bb0110","first-page":"1","article-title":"Marginalized populations and drug addiction research: Realism, mistrust, and misconception","volume":"30","author":"Fisher","year":"2008","journal-title":"IRB"},{"issue":"8","key":"10.1016\/j.jsat.2021.108667_bb0115","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1111\/j.1360-0443.2008.02252.x","article-title":"Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone","volume":"103","author":"Fishman","year":"2008","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2021.108667_bb0120","series-title":"Treatment trajectories during and after a medication trial for opioid use disorder: Moving from research as usual to treatment as usual","first-page":"331","volume":"14","author":"Fishman","year":"2020"},{"key":"10.1016\/j.jsat.2021.108667_bb0125","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.drugalcdep.2016.08.625","article-title":"Remission from substance use disorders: A systematic review and meta-analysis","volume":"168","author":"Fleury","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108667_bb0130","article-title":"Kari (48) har ruset seg i tjue \u00e5r. N\u00e5 holder Hun seg rusfri med \u00e9n spr\u00f8yte i m\u00e5neden (Kari (48) has been using drugs for 20 years. Now, she keeps clean with one shot each month.)","author":"Fosse","year":"2014","journal-title":"Bergensavisen"},{"key":"10.1016\/j.jsat.2021.108667_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108183","article-title":"Patients' perspectives on initiating treatment with extended-release naltrexone (XR-NTX)","volume":"122","author":"Gauthier","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"6","key":"10.1016\/j.jsat.2021.108667_bb0140","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/0269881106060835","article-title":"Naltrexone and buprenorphine combination in the treatment of opioid dependence","volume":"20","author":"Gerra","year":"2006","journal-title":"Journal of Psychopharmacology"},{"issue":"2","key":"10.1016\/j.jsat.2021.108667_bb0145","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002025.pub5","article-title":"Buprenorphine for managing opioid withdrawal","author":"Gowing","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1016\/j.jsat.2021.108667_bb0150","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1037\/0022-006X.64.6.1326","article-title":"Patients' view of the alliance of psychotherapy: Exploratory factor analysis of three alliance measures","volume":"64","author":"Hatcher","year":"1996","journal-title":"Journal of Consulting and Clinical Psychology"},{"issue":"2","key":"10.1016\/j.jsat.2021.108667_bb0155","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jpain.2018.09.001","article-title":"Patients\u2019 experience with opioid tapering: A conceptual model with recommendations for clinicians","volume":"20","author":"Henry","year":"2019","journal-title":"The Journal of Pain"},{"issue":"3","key":"10.1016\/j.jsat.2021.108667_bb0160","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1080\/07347324.2018.1424591","article-title":"Inpatient detoxification: Examining factors leading to early discharge","volume":"36","author":"Hogan","year":"2018","journal-title":"Alcoholism Treatment Quarterly"},{"issue":"1","key":"10.1016\/j.jsat.2021.108667_bb0165","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2307\/3564408","article-title":"Misunderstanding in clinical research: Distinguishing therapeutic misconception, therapeutic misestimation, and therapeutic optimism","volume":"25","author":"Horng","year":"2003","journal-title":"IRB"},{"key":"10.1016\/j.jsat.2021.108667_bb0170","series-title":"Beyond social constructionism: Critical realism and social work","first-page":"845","volume":"31","author":"Houston","year":"2001"},{"key":"10.1016\/j.jsat.2021.108667_bb0175","series-title":"Bjarne (48) har f\u00e5tt en spr\u00f8yte i m\u00e5neden i ett \u00e5r og er stoffri. \u2013 Det er godt \u00e5 v\u00e6re litt normal igjen (Bjarne (48) has received one shot each month and is drugfree. - 'It's nice to be a bit normal again')","author":"Hovden","year":"2019"},{"issue":"2","key":"10.1016\/j.jsat.2021.108667_bb0180","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/HRP.0000000000000052","article-title":"Long-term course of opioid addiction","volume":"23","author":"Hser","year":"2015","journal-title":"Harvard Review of Psychiatry"},{"issue":"12","key":"10.1016\/j.jsat.2021.108667_bb0185","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11920-020-01201-z","article-title":"Challenges for women entering treatment for opioid use disorder","volume":"22","author":"Huhn","year":"2020","journal-title":"Current Psychiatry Reports"},{"issue":"4","key":"10.1016\/j.jsat.2021.108667_bb0190","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1080\/1533256X.2020.1838859","article-title":"Risk factors for treatment drop-out: Implications for adverse outcomes when treating opioid use disorder","volume":"20","author":"Iovine","year":"2020","journal-title":"Journal of Social Work Practice in the Addictions"},{"issue":"1","key":"10.1016\/j.jsat.2021.108667_bb0195","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0306-4603(01)00210-6","article-title":"Hope as a predictor of entering substance abuse treatment","volume":"28","author":"Jackson","year":"2003","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.jsat.2021.108667_bb0200","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jsat.2016.12.006","article-title":"Factors associated with using opiates while under extended-release naltrexone blockade: A descriptive pilot study","volume":"85","author":"Jarvis","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"7","key":"10.1016\/j.jsat.2021.108667_bb0205","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/add.14180","article-title":"Extended-release injectable naltrexone for opioid use disorder: A systematic review","volume":"113","author":"Jarvis","year":"2018","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.jsat.2021.108667_bb0210","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/09515079908254078","article-title":"Intentionality and awareness: A qualitative study of clients' perceptions of change during longer term counselling","volume":"12","author":"Jinks","year":"1999","journal-title":"Counselling Psychology Quarterly"},{"issue":"8","key":"10.1016\/j.jsat.2021.108667_bb0215","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.4088\/JCP.13m08725","article-title":"Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults","volume":"75","author":"Karp","year":"2014","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1016\/j.jsat.2021.108667_bb0220","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0740-5472(02)00276-3","article-title":"Do patients' perceptions of their counselors influence outcomes of drug treatment?","volume":"23","author":"Kasarabada","year":"2002","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108667_bb0225","article-title":"Interventions before consultations for helping patients address their information needs","volume":"3","author":"Kinnersley","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1016\/j.jsat.2021.108667_bb0230","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s13643-021-01764-9","article-title":"Retention in opioid agonist treatment: A rapid review and meta-analysis comparing observational studies and randomized controlled trials","volume":"10","author":"Klimas","year":"2021","journal-title":"Systematic Reviews"},{"issue":"3","key":"10.1016\/j.jsat.2021.108667_bb0235","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/09595230500170241","article-title":"From opioid maintenance to abstinence: A literature review","volume":"24","author":"Kornor","year":"2005","journal-title":"Drug and Alcohol Review"},{"issue":"6","key":"10.1016\/j.jsat.2021.108667_bb0240","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/add.13753","article-title":"Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: A pilot\/feasibility randomized trial","volume":"112","author":"Korthuis","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2021.108667_bb0245","series-title":"Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services","first-page":"1683","volume":"115","author":"Krawczyk","year":"2020"},{"key":"10.1016\/j.jsat.2021.108667_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108329","article-title":"Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings","volume":"126","author":"Krawczyk","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"7","key":"10.1016\/j.jsat.2021.108667_bb9000","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/j.1360-0443.2007.01817.x","article-title":"Overcoming opioid blockade from depot naltrexone (Prodetoxon)","volume":"102","author":"Kruptisky","year":"2007","journal-title":"Addiction"},{"issue":"9","key":"10.1016\/j.jsat.2021.108667_bb0255","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/add.12208","article-title":"Injectable extended-release naltrexone (XR-NTX) for opioid dependence: Long-term safety and effectiveness","volume":"108","author":"Krupitsky","year":"2013","journal-title":"Addiction"},{"issue":"9776","key":"10.1016\/j.jsat.2021.108667_bb0260","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"The Lancet"},{"key":"10.1016\/j.jsat.2021.108667_bb0265","series-title":"Challenges to antagonist blockade during sustained-release naltrexone treatment","first-page":"1633","volume":"105","author":"Kun\u00f8e","year":"2010"},{"issue":"1","key":"10.1016\/j.jsat.2021.108667_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40360-016-0061-1","article-title":"Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX) [journal article]","volume":"17","author":"Kun\u00f8e","year":"2016","journal-title":"BMC Pharmacology and Toxicology"},{"key":"10.1016\/j.jsat.2021.108667_bb0275","first-page":"1","article-title":"Perspectives of people with opioid use disorder on improving addiction treatments and services","author":"Lachapelle","year":"2020","journal-title":"Drugs: Education, Prevention and Policy"},{"issue":"3","key":"10.1016\/j.jsat.2021.108667_bb0280","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jsat.2007.04.014","article-title":"What does recovery mean to you? Lessons from the recovery experience for research and practice","volume":"33","author":"Laudet","year":"2007","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"13","key":"10.1016\/j.jsat.2021.108667_bb0285","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","article-title":"Extended-release naltrexone to prevent opioid relapse in criminal justice offenders","volume":"374","author":"Lee","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.jsat.2021.108667_bb0290","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/add.12894","article-title":"Opioid treatment at release from jail using extended-release naltrexone: A pilot proof-of-concept randomized effectiveness trial","volume":"110","author":"Lee","year":"2015","journal-title":"Addiction"},{"issue":"10118","key":"10.1016\/j.jsat.2021.108667_bb0295","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"5335","key":"10.1016\/j.jsat.2021.108667_bb0300","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1126\/science.278.5335.45","article-title":"Addiction is a brain disease, and it matters","volume":"278","author":"Leshner","year":"1997","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.jsat.2021.108667_bb0305","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.addbeh.2006.02.004","article-title":"The role of drug use outcome expectancies in substance abuse risk: An interactional-transformational model","volume":"31","author":"Leventhal","year":"2006","journal-title":"Addictive Behaviors"},{"issue":"3\u20134","key":"10.1016\/j.jsat.2021.108667_bb0310","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0376-8716(85)90067-5","article-title":"Buprenorphine","volume":"14","author":"Lewis","year":"1985","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108667_bb0315","series-title":"SERAF RAPPORT 4\/2021 Statusrapport 2020 LAR behandling under f\u00f8rste \u00e5ret med Covid-19 pandemi","author":"Lobmaier","year":"2021"},{"key":"10.1016\/j.jsat.2021.108667_bb0320","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","volume":"3","author":"Mattick","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jsat.2021.108667_bb0325","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jsat.2021.108667_bb0330","series-title":"A realist approach for qualitative research","author":"Maxwell","year":"2012"},{"issue":"7","key":"10.1016\/j.jsat.2021.108667_bb0335","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1046\/j.1360-0443.2001.967104914.x","article-title":"Needle fixation, the drug user's perspective: A qualitative study","volume":"96","author":"McBride","year":"2001","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.jsat.2021.108667_bb0340","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.clpt.6100503","article-title":"Potential of buprenorphine\/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders","volume":"83","author":"McCann","year":"2008","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"6","key":"10.1016\/j.jsat.2021.108667_bb0345","first-page":"537","article-title":"Abstinence and drug abuse treatment: Results from the drug outcome research in Scotland study","volume":"13","author":"McKeganey","year":"2006","journal-title":"Drugs: Education, Prevention and Policy"},{"issue":"5","key":"10.1016\/j.jsat.2021.108667_bb0350","first-page":"423","article-title":"What are drug users looking for when they contact drug services: abstinence or harm reduction?","volume":"11","author":"McKeganey","year":"2004","journal-title":"Drugs: Education, Prevention and Policy"},{"key":"10.1016\/j.jsat.2021.108667_bb0355","doi-asserted-by":"crossref","DOI":"10.1001\/jama.284.13.1689","article-title":"Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation","volume":"284","author":"McLellan","year":"2000","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.jsat.2021.108667_bb0360","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00005053-198807000-00004","article-title":"Is the counselor an \"active ingredient\" in substance abuse rehabilitation? An examination of treatment success among four counselors","volume":"176","author":"McLellan","year":"1988","journal-title":"Journal of Nervous and Mental Disease"},{"issue":"3","key":"10.1016\/j.jsat.2021.108667_bb0365","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/npp.1993.57","article-title":"Naltrexone-buprenorphine interactions: Effects on cocaine self-administration","volume":"9","author":"Mello","year":"1993","journal-title":"Neuropsychopharmacology"},{"issue":"12\u201314","key":"10.1016\/j.jsat.2021.108667_bb0370","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3109\/10826080009148253","article-title":"Clinicians' impact on the quality of substance use disorder treatment","volume":"35","author":"Najavits","year":"2000","journal-title":"Substance Use & Misuse"},{"issue":"1-3","key":"10.1016\/j.jsat.2021.108667_bb0375","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.drugalcdep.2012.06.030","article-title":"Does recovery-oriented treatment prompt heroin users prematurely into detoxification and abstinence programmes? Qualitative study","volume":"127","author":"Neale","year":"2013","journal-title":"Drug Alcohol Dependence"},{"issue":"6","key":"10.1016\/j.jsat.2021.108667_bb0380","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1177\/0269881110364266","article-title":"Hospital psychiatric comorbidity and its role in heroin dependence treatment outcomes using naltrexone implant or methadone maintenance","volume":"25","author":"Ngo","year":"2011","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.jsat.2021.108667_bb0385","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jsat.2017.04.016","article-title":"Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone","volume":"85","author":"Nunes","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108667_bb0390","article-title":"N\u00e5la som kan redde liv (The needle that can save lives)","author":"\u00d8fsti","year":"2019","journal-title":"NRK"},{"key":"10.1016\/j.jsat.2021.108667_bb0395","series-title":"Risk of relapse among opioid-dependent patients treated with extended-release naltrexone or buprenorphine-naloxone: A randomized clinical trial","first-page":"453","volume":"30","author":"Opheim","year":"2021"},{"issue":"4","key":"10.1016\/j.jsat.2021.108667_bb0405","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1097\/ADM.0000000000000584","article-title":"Comparing reasons for starting and stopping methadone, buprenorphine, and naltrexone treatment among a sample of white individuals with opioid use disorder","volume":"14","author":"Randall-Kosich","year":"2020","journal-title":"Journal of Addiction Medicine"},{"issue":"3","key":"10.1016\/j.jsat.2021.108667_bb0410","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/02791072.2007.10400610","article-title":"Understanding the working alliance between persons with substance abuse problems and strengths-based case managers","volume":"39","author":"Redko","year":"2007","journal-title":"Journal of Psychoactive Drugs"},{"issue":"2","key":"10.1016\/j.jsat.2021.108667_bb0415","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/syn.890120206","article-title":"A review of the role of anti-opioid peptides in morphine tolerance and dependence","volume":"12","author":"Rothman","year":"1992","journal-title":"Synapse"},{"issue":"3","key":"10.1016\/j.jsat.2021.108667_bb0420","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0740-5472(99)00074-4","article-title":"An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence","volume":"18","author":"Rothman","year":"2000","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.jsat.2021.108667_bb0425","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0196-9781(91)90182-O","article-title":"Upregulation of the opioid receptor complex by the chronic administration of morphine: A biochemical marker related to the development of tolerance and dependence","volume":"12","author":"Rothman","year":"1991","journal-title":"Peptides"},{"key":"10.1016\/j.jsat.2021.108667_bb0430","doi-asserted-by":"crossref","DOI":"10.15714\/scandpsychol.2.e9","article-title":"Taking the plunge: Service users\u2019 experiences of hope within the mental health and substance use services","volume":"2","author":"S\u00e6l\u00f8r","year":"2015","journal-title":"Scandinavian Psychologist"},{"issue":"6","key":"10.1016\/j.jsat.2021.108667_bb0435","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000447964","article-title":"Interest in extended release naltrexone among opioid users","volume":"22","author":"Sharma Haase","year":"2016","journal-title":"European Addiction Research"},{"issue":"3","key":"10.1016\/j.jsat.2021.108667_bb0440","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/00952990.2011.653426","article-title":"Opioid detoxification and naltrexone induction strategies: Recommendations for clinical practice","volume":"38","author":"Sigmon","year":"2012","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"issue":"4","key":"10.1016\/j.jsat.2021.108667_bb0445","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/08897077.2019.1671942","article-title":"Understanding why patients with substance use disorders leave the hospital against medical advice: A qualitative study","volume":"41","author":"Simon","year":"2020","journal-title":"Substance Abuse"},{"issue":"6","key":"10.1016\/j.jsat.2021.108667_bb0450","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000501931","article-title":"Availability of extended-release naltrexone may increase the number of opioid-dependent individuals in treatment: Extension of a randomized clinical trial","volume":"25","author":"Solli","year":"2019","journal-title":"European Addiction Research"},{"key":"10.1016\/j.jsat.2021.108667_bb0455","article-title":"Adapting treatment length to opioid-dependent individuals' needs and preferences: A 2-year follow-up to a 1-year study of extended-release naltrexone","author":"Solli","year":"2020","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2021.108667_bb0460","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.jsat.2021.108667_bb0465","series-title":"Patients\u2019 and healthcare personnel\u2019s experiences with opioid maintenance treatment (OMT): A systematic review of qualitative studies","author":"Steiro","year":"2020"},{"key":"10.1016\/j.jsat.2021.108667_bb0470","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2016.16050548","article-title":"Long-acting injectable naltrexone induction: A randomized trial of outpatient opioid detoxification with naltrexone versus buprenorphine","author":"Sullivan","year":"2017","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.jsat.2021.108667_bb0475","first-page":"1","article-title":"Representation of adverse childhood experiences is associated with lower public stigma towards people who use drugs: an exploratory experimental study","author":"Sumnall","year":"2020","journal-title":"Drugs: Education, Prevention and Policy"},{"issue":"12","key":"10.1016\/j.jsat.2021.108667_bb0480","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: A randomized clinical noninferiority trial","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jsat.2021.108667_bb0485","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.brainres.2018.09.023","article-title":"Dynorphin\/kappa-opioid receptor control of dopamine dynamics: Implications for negative affective states and psychiatric disorders","volume":"1713","author":"Tejeda","year":"2019","journal-title":"Brain Research"},{"issue":"9 Pt 2","key":"10.1016\/j.jsat.2021.108667_bb0490","first-page":"42","article-title":"Clinical experience with naltrexone in suburban opioid addicts","volume":"45","author":"Tennant","year":"1984","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.jsat.2021.108667_bb0495","series-title":"National practice guidelines for detoxification from legal and illegal substances","year":"2016"},{"issue":"1","key":"10.1016\/j.jsat.2021.108667_bb0500","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/10550887.2020.1811456","article-title":"Assessing perceptions about medications for opioid use disorder and naloxone on twitter","volume":"39","author":"Tofighi","year":"2020","journal-title":"Journal of Addictive Diseases"},{"issue":"3","key":"10.1016\/j.jsat.2021.108667_bb0505","first-page":"272","article-title":"Treatment satisfaction and quality of support in outpatient substitution treatment: Opiate users\u2019 experiences and perspectives","volume":"22","author":"Vanderplasschen","year":"2015","journal-title":"Drugs: Education, Prevention and Policy"},{"key":"10.1016\/j.jsat.2021.108667_bb0510","article-title":"Ny spr\u00f8yte hjalp Aleksander ut av rusavhengighet (New \u201cshot\u201d helped Aleksander out of addiction)","author":"Vebenstad","year":"2017","journal-title":"NRK"},{"issue":"1","key":"10.1016\/j.jsat.2021.108667_bb0515","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13722-019-0166-0","article-title":"Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail","volume":"14","author":"Velasquez","year":"2019","journal-title":"Addiction Science & Clinical Practice"},{"issue":"3","key":"10.1016\/j.jsat.2021.108667_bb0520","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cpt1976203315","article-title":"Naltrexone: Disposition, metabolism, and effects after acute and chronic dosing","volume":"20","author":"Verebey","year":"1976","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"1","key":"10.1016\/j.jsat.2021.108667_bb0525","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40737-019-00137-9","article-title":"A stabilizing and destabilizing social world: Close relationships and recovery processes in SUD","volume":"6","author":"Veseth","year":"2019","journal-title":"Journal of Psychosocial Rehabilitation and Mental Health"},{"key":"10.1016\/j.jsat.2021.108667_bb0530","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.drugpo.2016.09.003","article-title":"Rethinking retention in treatment of opioid dependence-the eye of the beholder","volume":"39","author":"Vogel","year":"2017","journal-title":"The International Journal on Drug Policy"},{"issue":"2","key":"10.1016\/j.jsat.2021.108667_bb0535","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1016\/j.jsat.2021.108667_bb0540","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/10826080802525967","article-title":"Retention in Treatment\u2014Indicator or illusion: An essay","volume":"44","author":"Walker","year":"2009","journal-title":"Substance Use & Misuse"},{"issue":"2","key":"10.1016\/j.jsat.2021.108667_bb0545","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00213-010-1825-8","article-title":"The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse","volume":"210","author":"Wee","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jsat.2021.108667_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2021.100728","article-title":"Enablers and hindrances for longer-term abstinence in opioid dependent individuals receiving treatment with extended-release naltrexone: A Norwegian longitudinal recovery trial (NaltRec study)","volume":"21","author":"Weimand","year":"2021","journal-title":"Contemporary Clinical Trials Communications"},{"issue":"4","key":"10.1016\/j.jsat.2021.108667_bb0555","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/ajad.12527","article-title":"Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders","volume":"26","author":"Williams","year":"2017","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.jsat.2021.108667_bb0560","series-title":"Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder","first-page":"117","volume":"177","author":"Williams","year":"2020"},{"key":"10.1016\/j.jsat.2021.108667_bb0565","series-title":"United Nations publication, Issue","year":"2020"},{"issue":"14","key":"10.1016\/j.jsat.2021.108667_bb0570","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1080\/10826084.2016.1201117","article-title":"Acceptability of extended-release naltrexone by heroin-dependent patients and addiction treatment providers in the Netherlands","volume":"51","author":"Zaaijer","year":"2016","journal-title":"Substance Use & Misuse"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221003937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221003937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:56:57Z","timestamp":1760039817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547221003937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":114,"alternative-id":["S0740547221003937"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108667","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u2018Not at all what I had expected\u2019: Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108667","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108667"}}